BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang HH, He Y, Wang HX, Liao CL, Peng Y, Tao LJ, Zhang W, Yang HX. Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(8): 941-948 [PMID: 29491687 DOI: 10.3748/wjg.v24.i8.941] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
2 Ye BD, Travis S. Improving the quality of care for inflammatory bowel disease. Intest Res 2019;17:45-53. [PMID: 30449081 DOI: 10.5217/ir.2018.00113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
3 Chang JY, Park SJ, Jung ES, Jung SA, Moon CM, Chun J, Park JJ, Kim ES, Park Y, Kim TI, Kim WH, Cheon JH. Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 2010-2018. e2. [PMID: 31446180 DOI: 10.1016/j.cgh.2019.08.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
4 Fei X, Shu Q, Zhu H, Hua B, Wang S, Guo L, Fang Y, Ge W. NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients. Front Pharmacol 2018;9:460. [PMID: 29867468 DOI: 10.3389/fphar.2018.00460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Khaeso K, Udayachalerm S, Komvilaisak P, Chainansamit S, Suwannaying K, Laoaroon N, Kuwatjanakul P, Nakkam N, Sukasem C, Puangpetch A, Tassaneeyakul W, Chaiyakunapruk N. Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations. Front Pharmacol 2021;12:784712. [DOI: 10.3389/fphar.2021.784712] [Reference Citation Analysis]
6 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Park YE, Kim TO. Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease. World J Mens Health 2020;38:285-97. [PMID: 30929327 DOI: 10.5534/wjmh.190007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
8 Zhou X, Cheng L, Wang Y, Gou H, Ju K, Lan T, Zhan T, Li G, Gu Y, Sun Y, Xu Y, Sun Y, Zhou Y, Li W. Effect of NUDT15 polymorphisms on early hematological safety of low-dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study. J Dermatol 2021. [PMID: 34866237 DOI: 10.1111/1346-8138.16265] [Reference Citation Analysis]
9 Zeng D, Huang X, Lin S, Lin R, Weng X, Huang P. Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data. Ann Transl Med 2021;9:1138. [PMID: 34430579 DOI: 10.21037/atm-21-1980] [Reference Citation Analysis]
10 Lee HS, Jo KW, Shim TS, Song JW, Lee HJ, Hwang SW, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH, Yang SK. Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease. J Crohns Colitis 2015;9:1053-7. [PMID: 26221002 DOI: 10.1093/ecco-jcc/jjv135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4-16. [PMID: 29422793 DOI: 10.5217/ir.2018.16.1.4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
12 Zhu X, Chao K, Li M, Xie W, Zheng H, Zhang JX, Hu PJ, Huang M, Gao X, Wang XD. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients. World J Gastroenterol 2019; 25(38): 5850-5861 [PMID: 31636477 DOI: 10.3748/wjg.v25.i38.5850] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Kang B, Kim TJ, Choi J, Baek SY, Ahn S, Choi R, Lee SY, Choe YH. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers. Aliment Pharmacol Ther 2020;52:459-70. [PMID: 32598049 DOI: 10.1111/apt.15810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kushner CJ, Concha JSS, Werth VP. Treatment of Autoimmune Bullous Disorders in Pregnancy. Am J Clin Dermatol 2018;19:391-403. [DOI: 10.1007/s40257-018-0342-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Eun CS. Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients? Gut Liver 2017;11:3-4. [PMID: 28053295 DOI: 10.5009/gnl16574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
18 Xu Y, Qiao YQ, Li HY, Zhou M, Cai CW, Shen J, Ran ZH. NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy. Gastroenterol Rep (Oxf) 2020;8:437-44. [PMID: 33442476 DOI: 10.1093/gastro/goaa021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Chao K, Huang Y, Zhu X, Tang J, Wang X, Lin L, Guo H, Zhang C, Li M, Yang Q, Huang J, Ye L, Hu P, Huang M, Cao Q, Gao X. Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther 2021;54:1124-33. [PMID: 34563096 DOI: 10.1111/apt.16600] [Reference Citation Analysis]
20 Fan X, Yin D, Men R, Xu H, Yang L. NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis. Front Pharmacol 2019;10:346. [PMID: 31024313 DOI: 10.3389/fphar.2019.00346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
22 Zhou XL, Zhan TY, Zhou YH, Shrestha K, Lan TJ, Li W. Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone. Dermatol Ther 2020;33:e14079. [PMID: 32713039 DOI: 10.1111/dth.14079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu P, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang S. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment: AOCC & APAGE consensus on TB in IBD-Part 1. Journal of Gastroenterology and Hepatology 2018;33:20-9. [DOI: 10.1111/jgh.14019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Miao Q, Yan L, Zhou Y, Li Y, Zou Y, Wang L, Bai Y, Zhang J. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci Rep 2021;11:7984. [PMID: 33846471 DOI: 10.1038/s41598-021-87095-0] [Reference Citation Analysis]
25 Sato T, Takagawa T, Kakuta Y, Nishio A, Kawai M, Kamikozuru K, Yokoyama Y, Kita Y, Miyazaki T, Iimuro M, Hida N, Hori K, Ikeuchi H, Nakamura S. NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest Res 2017;15:328-37. [PMID: 28670229 DOI: 10.5217/ir.2017.15.3.328] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
26 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
27 Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med 2018;33:28-35. [PMID: 29334728 DOI: 10.3904/kjim.2017.400] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lee JM, Lee KM, Kim JS, Kim YS, Cheon JH, Ye BD, Kim YH, Han DS, Lee CK, Park HJ. Postoperative course of Crohn disease according to timing of bowel resection: Results from the CONNECT Study. Medicine (Baltimore) 2018;97:e0459. [PMID: 29668618 DOI: 10.1097/MD.0000000000010459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Bae J, Choe BH, Kang B. Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn's disease who turned out to possess homozygous mutations in NUDT15 R139C. Yeungnam Univ J Med 2020;37:332-6. [PMID: 32438538 DOI: 10.12701/yujm.2020.00178] [Reference Citation Analysis]
30 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
31 Zhu X, Wang XD, Chao K, Zhi M, Zheng H, Ruan HL, Xin S, Ding N, Hu PJ, Huang M, Gao X. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease. Aliment Pharmacol Ther. 2016;44:967-975. [PMID: 27604507 DOI: 10.1111/apt.13796] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
32 Cargnin S, Genazzani AA, Canonico PL, Terrazzino S. Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacological Research 2018;135:102-11. [DOI: 10.1016/j.phrs.2018.07.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
33 Özgenç F, Karakoyun M, Ecevit Ç, Hekimci H, Kıran Taşçı E, Erdemir G. Efficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experience. Turk J Gastroenterol 2018;29:650-4. [PMID: 30381272 DOI: 10.5152/tjg.2018.17151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Park S, Hong M, Ye BD, Kim K, Park SH, Yang D, Hwang S, Kwak MS, Lee H, Song K, Yang S. Influences of XDH genotype by gene–gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:684-91. [DOI: 10.3109/00365521.2015.1133698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
36 Liu Q, Wang Y, Mei Q, Han W, Hu J, Hu N. Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients. Scand J Gastroenterol 2016;51:1093-9. [PMID: 27152547 DOI: 10.3109/00365521.2016.1161068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
37 Park SH, Hwang SW, Kwak MS, Kim WS, Lee JM, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS. Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study. Dig Dis Sci. 2016;61:2060-2067. [PMID: 26971089 DOI: 10.1007/s10620-016-4105-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
38 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
39 Chao K, Wang X, Cao Q, Qian J, Wu K, Zhu X, Yang H, Liang J, Lin L, Huang Z, Zhang Y, Huang Y, Sun Y, Xue X, Huang M, Hu P, Lan P, Gao X. Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis. Inflamm Bowel Dis. 2017;23:1592-1599. [PMID: 28570428 DOI: 10.1097/mib.0000000000001148] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
40 Im JP. Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease? Intest Res 2017;15:147-8. [PMID: 28522942 DOI: 10.5217/ir.2017.15.2.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Lee HS, Choe J, Lee HJ, Hwang SW, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ. Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea. Intest Res. 2016;14:258-263. [PMID: 27433148 DOI: 10.5217/ir.2016.14.3.258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
43 Song KH, Kim ES, Lee YJ, Jang BI, Kim KO, Kwak SG, Lee HS; Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD). Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis. Intest Res 2018;16:216-22. [PMID: 29743834 DOI: 10.5217/ir.2018.16.2.216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
45 Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci 2019;64:2395-403. [PMID: 31290039 DOI: 10.1007/s10620-019-05720-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]